Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 18, 2022 16:05 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Announces Fiscal 2021 Financial Results and Provides Business Update

REDWOOD CITY, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on transforming the field of hematopoietic stem cell therapies,...
March 10, 2022 08:00 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference

REDWOOD CITY, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that...
February 28, 2022 08:00 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Announces Appointment of Ronald Martell as Chief Executive Officer

REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced the...
February 24, 2022 17:19 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Announces JSP191 Phase 1b MDS/AML Late Breaking Data Presentation at the 2022 Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR

JSP191 is well tolerated with no treatment-related severe adverse events in 17 subjects with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in Ph1b dose expansion study17 of 17...
December 08, 2021 08:30 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics to Present Data on JSP191 Conditioning in SCID patients at the 2021 American Society of Hematology Annual Meeting

JSP191 is well tolerated with no treatment-related adverse events in dose-escalation studySingle-agent conditioning with JSP191 is associated with engraftment, immune reconstitution, and clinical...
November 12, 2021 16:05 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update

REDWOOD CITY, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced results...
November 09, 2021 08:00 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Announces Research Collaboration with AVROBIO to Evaluate JSP191 as Conditioning Agent in Clinical Studies of Ex Vivo Lentiviral Gene Therapy

REDWOOD CITY, Calif. and CAMBRIDGE, Mass. , Nov. 09, 2021 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on hematopoietic stem cell therapeutics, today...
November 08, 2021 08:00 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics to Present at the Credit Suisse 30th Annual Virtual Healthcare Conference

REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that...